183 related articles for article (PubMed ID: 32241284)
1. Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit.
Bertero L; Spadi R; Osella-Abate S; Mariani S; Castellano I; Gambella A; Racca P; Morino M; Cassoni P
World J Surg Oncol; 2020 Apr; 18(1):65. PubMed ID: 32241284
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort.
Rouyer M; François E; Cunha AS; Monnereau A; Noize P; Robinson P; Droz-Perroteau C; Le Monies de Sagazan A; Jové J; Lassalle R; Moore N; Fourrier-Réglat A; Smith D;
Clin Colorectal Cancer; 2018 Jun; 17(2):129-139. PubMed ID: 29523416
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.
Vincenzi B; Cremolini C; Sartore-Bianchi A; Russo A; Mannavola F; Perrone G; Pantano F; Loupakis F; Rossini D; Ongaro E; Bonazzina E; Dell'Aquila E; Imperatori M; Zoccoli A; Bronte G; De Maglio G; Fontanini G; Natoli C; Falcone A; Santini D; Onetti-Muda A; Siena S; Tonini G; Aprile G
Oncotarget; 2015 Oct; 6(31):31604-12. PubMed ID: 26384309
[TBL] [Abstract][Full Text] [Related]
4. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J
Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311
[TBL] [Abstract][Full Text] [Related]
5. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
Bencsikova B; Budinska E; Selingerova I; Pilatova K; Fedorova L; Greplova K; Nenutil R; Valik D; Obermannova R; Sheard MA; Zdrazilova-Dubska L
BMC Cancer; 2019 Jul; 19(1):687. PubMed ID: 31307428
[TBL] [Abstract][Full Text] [Related]
6. An Analysis of Relationship Between RAS Mutations and Prognosis of Primary Tumour Resection for Metastatic Colorectal Cancer Patients.
Liang L; Tian J; Yu Y; Wang Z; Peng K; Liu R; Wang Y; Xu X; Li H; Zhuang R; Cui Y; Zhu C; Liu T
Cell Physiol Biochem; 2018; 50(2):768-782. PubMed ID: 30308491
[TBL] [Abstract][Full Text] [Related]
7. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern.
Prasanna T; Karapetis CS; Roder D; Tie J; Padbury R; Price T; Wong R; Shapiro J; Nott L; Lee M; Chua YJ; Craft P; Piantadosi C; Sorich M; Gibbs P; Yip D
Acta Oncol; 2018 Nov; 57(11):1438-1444. PubMed ID: 30035653
[TBL] [Abstract][Full Text] [Related]
8. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients.
Daitoku N; Miyamoto Y; Sakamoto Y; Tokunaga R; Hiyoshi Y; Nagai Y; Iwatsuki M; Iwagami S; Yoshida N; Baba H
Int J Clin Oncol; 2020 Apr; 25(4):651-659. PubMed ID: 31834556
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of primary tumor resection and lymph node dissection in stage IV colorectal cancer with unresectable metastasis: a propensity score analysis in a multicenter retrospective study.
Ishihara S; Hayama T; Yamada H; Nozawa K; Matsuda K; Miyata H; Yoneyama S; Tanaka T; Tanaka J; Kiyomatsu T; Kawai K; Nozawa H; Kanazawa T; Kazama S; Yamaguchi H; Sunami E; Kitayama J; Hashiguchi Y; Sugihara K; Watanabe T
Ann Surg Oncol; 2014 Sep; 21(9):2949-55. PubMed ID: 24763981
[TBL] [Abstract][Full Text] [Related]
11. Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience.
Jin Z; Sanhueza CT; Johnson B; Nagorney DM; Larson DW; Mara KC; Harmsen WC; Smyrk TC; Grothey A; Hubbard JM
Oncologist; 2018 Sep; 23(9):1083-1091. PubMed ID: 29674439
[TBL] [Abstract][Full Text] [Related]
12. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
13. Impact of Metastasectomy in the Multimodality Approach for
Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
15. Clinical features and prognosis in hepatectomy for colorectal cancer with centrally located liver metastasis.
Kuo IM; Huang SF; Chiang JM; Yeh CY; Chan KM; Chen JS; Yu MC
World J Surg Oncol; 2015 Mar; 13():92. PubMed ID: 25889950
[TBL] [Abstract][Full Text] [Related]
16. [Surgical treatment of metastases and its impact on prognosis in patients with metastatic colorectal carcinoma].
Sevčíková K; Ušáková V; Bartošová Z; Sabol M; Ondrušová M; Ondruš D; Spánik S
Klin Onkol; 2014; 27(1):38-44. PubMed ID: 24635436
[TBL] [Abstract][Full Text] [Related]
17. Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy.
Demircan NC; Dane F; Ozturk MA; Babacan NA; Besiroglu M; Kaya S; Ercelep O; Tanrikulu E; Halil S; Koca S; Alan O; Hasanov R; Yumuk PF
J BUON; 2019; 24(4):1494-1500. PubMed ID: 31646797
[TBL] [Abstract][Full Text] [Related]
18. Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
Rouyer M; Smith D; Laurent C; Becouarn Y; Guimbaud R; Michel P; Tubiana-Mathieu N; Balestra A; Jové J; Robinson P; Noize P; Moore N; Ravaud A; Fourrier-Réglat A;
Target Oncol; 2016 Feb; 11(1):83-92. PubMed ID: 26298481
[TBL] [Abstract][Full Text] [Related]
19. Treatment Modalities and Survival in Older Adults with Metastatic Colorectal Cancer in Real Life.
Gouverneur A; Bezin J; Jové J; Bosco-Lévy P; Fourrier-Réglat A; Noize P
J Am Geriatr Soc; 2019 May; 67(5):913-919. PubMed ID: 30840323
[TBL] [Abstract][Full Text] [Related]
20. Modern-day palliative chemotherapy for metastatic colorectal cancer: does colonic resection affect survival?
Lau JWL; Chang HSY; Lee KY; Gwee YX; Lee WQ; Chong CS
ANZ J Surg; 2018 Nov; 88(11):E772-E777. PubMed ID: 29938886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
